Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

98 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The effect of interferon-beta on black holes in patients with multiple sclerosis.
Bagnato F, Evangelou IE, Gallo A, Gaindh D, Yao K. Bagnato F, et al. Expert Opin Biol Ther. 2007 Jul;7(7):1079-91. doi: 10.1517/14712598.7.7.1079. Expert Opin Biol Ther. 2007. PMID: 17665995 Review.
Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a.
Antonelli G, Bagnato F, Pozzilli C, Simeoni E, Bastianelli S, Currenti M, De Pisa F, Fieschi C, Gasperini C, Salvetti M, Dianzani F. Antonelli G, et al. J Interferon Cytokine Res. 1998 May;18(5):345-50. doi: 10.1089/jir.1998.18.345. J Interferon Cytokine Res. 1998. PMID: 9620362
Determinants of Gd-enhanced MRI response to IFN-beta-1a treatment in relapsing-remitting multiple sclerosis.
Koudriavtseva T, Pozzilli C, Fiorelli M, Gasperini C, Bagnato F, Galgani S, Frontoni M, Ciccarelli O, Bastianello S. Koudriavtseva T, et al. Mult Scler. 1998 Oct;4(5):403-7. doi: 10.1177/135245859800400501. Mult Scler. 1998. PMID: 9839299 Clinical Trial.
Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.
Antonelli G, Simeoni E, Bagnato F, Pozzilli C, Turriziani O, Tesoro R, Di Marco P, Gasperini C, Fieschi C, Dianzani F. Antonelli G, et al. J Neurol Sci. 1999 Oct 15;168(2):131-6. doi: 10.1016/s0022-510x(99)00185-9. J Neurol Sci. 1999. PMID: 10526196 Clinical Trial.
Contrast-enhanced magnetic resonance activity in relapsing remitting multiple sclerosis patients: a short term natural history study.
Bagnato F, Tancredi A, Richert N, Gasperini C, Bastianello S, Bash C, McFarland H, Pozzilli C, Frank JA. Bagnato F, et al. Mult Scler. 2000 Feb;6(1):43-9. doi: 10.1177/135245850000600109. Mult Scler. 2000. PMID: 10694845 Clinical Trial.
Neutralizing and binding antibodies to IFN-beta: relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-beta preparations.
Scagnolari C, Bellomi F, Turriziani O, Bagnato F, Tomassini V, Lavolpe V, Ruggieri M, Bruschi F, Meucci G, Dicuonzo G, Antonelli G. Scagnolari C, et al. J Interferon Cytokine Res. 2002 Feb;22(2):207-13. doi: 10.1089/107999002753536176. J Interferon Cytokine Res. 2002. PMID: 11911803
Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis.
Pozzilli C, Antonini G, Bagnato F, Mainero C, Tomassini V, Onesti E, Fantozzi R, Galgani S, Pasqualetti P, Millefiorini E, Spadaro M, Dahlke F, Gasperini C. Pozzilli C, et al. J Neurol. 2002 Jan;249(1):50-6. doi: 10.1007/pl00007847. J Neurol. 2002. PMID: 11954868 Clinical Trial.
MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
Gasperini C, Paolillo A, Giugni E, Galgani S, Bagnato F, Mainero C, Onesti E, Bastianello S, Pozzilli C. Gasperini C, et al. Mult Scler. 2002 Apr;8(2):119-23. doi: 10.1191/1352458502ms788oa. Mult Scler. 2002. PMID: 11990868
A one-year study on the pharmacodynamic profile of interferon-beta1a in MS.
Bagnato F, Pozzilli C, Scagnolari C, Bellomi F, Pasqualetti P, Gasperini C, Millefiorini E, Galgani S, Spadaro M, Antonelli G. Bagnato F, et al. Neurology. 2002 May 14;58(9):1409-11. doi: 10.1212/wnl.58.9.1409. Neurology. 2002. PMID: 12011292 Clinical Trial.
98 results
Jump to page
Feedback